SURF News and Press, Surface Oncology Inc. From 03/31/22

CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the first patient has been dosed by GlaxoSmithKline (GSK)...

Buying Penny Stocks Today? Here’s What You Need to Know With another volatile day of trading for penny stocks and blue chips here, there is a lot for investors to understand. Now, trading penny stocks is not easy, and this is especially true in March 2022. With a war going on...

Surface Oncology press release (NASDAQ:SURF): Q4 GAAP EPS of -$0.52 misses by $0.43. Revenue of $0.15M (-99.8% Y/Y) misses by $16.18M. Shares +1.65% PM. For further details see: Surface Oncology GAAP EPS of -$0.52 misses by $0.43, revenue of $0.15M misses by $16.18M

Continued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types Company continues to guide to cash runway through 2023 CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWS...

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will partici...

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that company management will participate in a fireside cha...

Biopharma veteran Ben Hickey appointed to Board of Directors Lisa McGrath promoted to chief people officer; Shannon Devens promoted to senior vice president, development operations CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF),...

CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that new data from the ongoing Phase 1 study of SRF617, an...

CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Surface Oncology , a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company was named one of the Top Places to Work in Massachusett...

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation sharing new clinical data from ...